Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nautilus Biotechnology (NAUT) Cash & Equivalents (2020 - 2026)

Nautilus Biotechnology has reported Cash & Equivalents over the past 7 years, most recently at $14.6 million for Q1 2026.

  • Quarterly results put Cash & Equivalents at $14.6 million for Q1 2026, down 56.0% from a year ago — trailing twelve months through Mar 2026 was $14.6 million (down 56.0% YoY), and the annual figure for FY2025 was $12.4 million, down 55.19%.
  • Cash & Equivalents reached $14.6 million in Q1 2026 per NAUT's latest filing, up from $12.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $210.4 million in Q2 2022 and bottomed at $4.4 million in Q3 2024.
  • Median Cash & Equivalents over the past 5 years was $33.2 million (2025), compared with a mean of $68.1 million.
  • The largest annual shift saw Cash & Equivalents skyrocketed 27556.78% in 2022 before it tumbled 94.05% in 2024.
  • Over 5 years, Cash & Equivalents stood at $114.5 million in 2022, then plummeted by 83.06% to $19.4 million in 2023, then surged by 42.53% to $27.6 million in 2024, then plummeted by 55.19% to $12.4 million in 2025, then grew by 18.07% to $14.6 million in 2026.
  • Business Quant data shows Cash & Equivalents for NAUT at $14.6 million in Q1 2026, $12.4 million in Q4 2025, and $23.9 million in Q3 2025.